Search results
Focus: Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters· 3 days ago, opens new tab Zepbound can cut heart disease risk, treat sleep apnea and address other health...
What a Year on Ozempic Taught Johann Hari
The Atlantic· 6 days agoIn the fall of 2005, Johann Hari, then a young columnist for The Independent who was struggling with his weight, described a trip he said he’d taken to a...
NodThera's NLRP3 inhibitor shows further anti-inflammatory promise in phase 1b/2a obesity trial
FierceBiotech· 1 day agoNodThera’s NLRP3 inhibitor has already proved its worth against Novo Nordisk’s blockbuster obesity drug in preclinical trials. Now, an early readout from a study in humans with obesity has again ...
Why 'if it's too good to be true, it's a scam' is wise online advice
Rolling Out· 3 days agoIn the vast and often overwhelming world of the internet, the phrase “if it’s too good to be true,...
More People — Including Children — Are Being Intentionally Poisoned in the U.S.
People Magazine· 2 days agoIntentional poisoning deaths in the United States have risen a staggering amount — and the number of...
Is Eli Lilly and Company (LLY) A Good “Quality Stock” to Buy Now?
Insider Monkey via Yahoo Finance· 7 days agoWe recently compiled the list of the 13 Best Quality Stocks To Buy according to the hedge funds...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
Morningstar· 5 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...
Salty guts, poop and rowing: The week in Well+Being
Washington Post· 7 days agoIndoor rowing is an efficient workout that can exercise your muscles in a short period. This week, reporter Teddy Amenabar and senior video journalist...
Vets Share The Most Common Signs Of Lyme Disease In Dogs
HuffPost Life via Yahoo News· 7 days ago“It’s an acute kidney injury, there’s kidney failure and proteinloss into the urine, and that can be...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 5 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...